(Q64379779)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

S Jain

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

K L Rosenthal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

27 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

539-553

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21525865%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/mi.2011.21

29 January 2020

exact match

0 references

cites work

HIV-1-specific antibody responses during acute and chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Fc receptor but not complement binding is important in antibody protection against HIV.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Fc receptor-mediated antiviral antibodies

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Cross-Clade HIV-1–Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1–Exposed, Persistently Seronegative Subjects

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgM

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Intraepithelial cell neutralization of HIV-1 replication by IgA.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

HIV-Specific Antibodies But Not T-Cell Responses Are Associated With Protection in Seronegative Partners of HIV-1-Infected Individuals in Cambodia

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583-599) of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

B Cell Epitope Mapping of Human Immunodeficiency Virus Envelope Glycoproteins with Long (19- to 36-residue) Synthetic Peptides

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Three-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Variation in class-specific humoral immune responses of different mouse strains to microfilariae of Dipetalonema viteae.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

IgA antibody as a non-inflammatory regulator of immunity

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

A comparative analysis of gene expression patterns and cell phenotypes between cervical and peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

The mucosal barrier and immune activation in HIV pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

The liver and IgA: immunological, cell biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

The immune response during acute HIV-1 infection: clues for vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

B1b lymphocytes confer T cell-independent long-lasting immunity

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Rapid induction of splenic and peritoneal B-1a cells in adult mice by thymus-independent type-2 antigen

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Dual role for B-1a cells in immunity to influenza virus infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Type I Interferon Production Is Profoundly and Transiently Impaired in Primary HIV‐1 Infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Type I interferon production in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

A common epitope on gp41, IFN-alpha and IFN-beta induces protective activity

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

HIV-1 gp41 and type I interferon: sequence homology and biological as well as clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Effects of type I/type II interferons and transforming growth factor-beta on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Innate immune activation in primary HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Measuring HIV neutralization in a luciferase reporter gene assay

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021

Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier

1 reference

https://api.crossref.org/works/10.1038%2FMI.2011.21

7 January 2021